<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23509">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02081313</url>
  </required_header>
  <id_info>
    <org_study_id>C12-56</org_study_id>
    <secondary_id>2013-A00275-40</secondary_id>
    <nct_id>NCT02081313</nct_id>
  </id_info>
  <brief_title>Natural History and Biological Study of Netherton Syndrome</brief_title>
  <acronym>NSnatbio</acronym>
  <official_title>Syndrome de Netherton : Aspects Cliniques, Physiopathologiques et Identification de Cibles thérapeutiques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at studying the natural history of Netherton syndrome (NS), to identify the
      consequences of LEKTI deficiency on the immune system and to characterize new molecular
      mechanisms involved in the disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Measurement of seric cytokines levels</measure>
    <time_frame>3 months after patient recruitment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pattern of skin abnormalities</measure>
    <time_frame>3 months after patient recruitment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Netherton Syndrome</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Netherton syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Netherton syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <arm_group_label>Netherton syndrome</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Netherton syndrome</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult or child (no age limit)

          -  Confirmed diagnosis of Netherton syndrome

          -  Signed informed consent form for the patient or his legal representative

        Exclusion Criteria:

          -  Bleeding disorder precluding skin biopsy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Hovnanian, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM U1163</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain Hovnanian, MD, PhD</last_name>
    <phone>33142754289</phone>
    <email>alain.hovnanian@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laetitia Furio, PhD</last_name>
    <phone>33142754368</phone>
    <email>laetitia.furio@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imagine Institute for genetic diseases</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alain Hovnanian, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Netherton syndrome</keyword>
  <keyword>Immune system</keyword>
  <keyword>Skin barrier</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Netherton Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
